Article
Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.
Gynecologic oncology - 1 Nov 2010
Vijayaraghavan Arthi, Efrusy Molly B, Goodman Karyn A, Santas Christopher C, Huh Warner K
Abstract excerpt
OBJECTIVE: Testing for human papillomavirus (HPV) 16 and 18 genotypes, which are known to cause approximately 65-70% of invasive cervical cancer cases, may allow clinicians to identify women at highest risk for underlying cervical intraepithelial neoplasia missed by Pap cytology. Our objective was to determine the cost-effectiveness of adding HPV-16 and 18 genotype triage to current cervical cancer screening...
Topics
- Adolescent
- Adult
- Child
- Child, Preschool
- Cost-Benefit Analysis
- Female
- Genotype
- Human papillomavirus 16
- Human papillomavirus 18
- Humans
- Incidence
- Markov Chains
- Mass Screening
- Monte Carlo Method
- Papillomavirus Infections